Alafair Biosciences, Inc.- formerly DBA Alafair Biotechnology, Inc. - specializes in the development and commercialization of biomaterials and biomedical devices to enhance internal wound healing. The firm's initial technology, licensed exclusively from and developed with the University of Texas at Austin, is a hydrogel membrane that provides support during post-surgical critical wound healing. The company develops cross-linked polysaccharide hydrogel films to address the post-surgical complication of unwanted soft tissue attachments or tethering between opposing tissue surfaces. It also develops membrane, bilayer, and injectable gel solutions for applications in scar prevention, wound care, and tissue reconstruction. The firm's follow-on product pipeline includes membrane, bilayer, and injectable gel solutions for applications in scar prevention, wound care, and tissue reconstruction. Alafairâs initial product is a film that exhibits superior handling and mechanical properties as compared to competing products, with preliminary in vivo studies showing promising soft tissue reconstruction and degradation results.
